Exicure, Inc. (XCUR) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Exicure, Inc. for the period ended September 30, 2025. Exicure is a smaller reporting company and non-accelerated filer. Historically an early-stage biotechnology firm, the company suspended its original R&D in 2022 to explore strategic alternatives. In January 2025, Exicure acquired GPCR Therapeutics USA Inc. ("GPCR USA"), a subsidiary focused on a Phase 2 clinical trial for blood cancer (Multiple Myeloma). The company also formed a South Korean subsidiary, KC Creation, in March 2025 to explore renewable energy and entertainment content opportunities.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $500,000 |
| Net Loss | $(2,437,000) | $(1,091,000) | $(2,048,000) | $(2,520,000) |
| Operating Expenses | $2,391,000 | $2,572,000 | $1,977,000 | $5,143,000 |
| Cash and Equivalents (End of Period) | $4,438,000 | $951,000 | $4,438,000 | $951,000 |
| Contingent Consideration Liability | $5,787,000 | $0 | $5,787,000 | $0 |
Liquidity: Cash decreased by $8.1 million during the nine months ended September 30, 2025, driven by operating cash outflows of $7.4 million and investing outflows of $2.3 million (primarily the GPCR USA acquisition). Financing activities provided $1.6 million via common stock offerings.
Material Changes vs. Prior Period
- Acquisition Impact: The acquisition of GPCR USA in Q1 2025 introduced significant R&D expenses ($2.6 million YTD 2025 vs. $0 YTD 2024) and a contingent consideration liability of approximately $5.8 million.
- Revenue Decline: Revenue dropped to zero in 2025 compared to $500,000 in 2024, which was derived from a one-time patent license agreement.
- Lease Termination Gain: The YTD 2024 results included a $6.0 million non-cash gain from the early termination of the Chicago lease, which significantly reduced the operating loss for that period. This gain did not recur in 2025.
- Legal Settlements: In Q3 2025, the company satisfied a $1.0 million self-insured retainer obligation related to a securities class action settlement, resulting in a $155,000 gain on settlement of accounts payable.
Outlook, Risks, and Management Commentary
Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months. Current cash of $4.4 million is deemed insufficient to fund operations, support GPCR USA's clinical trial, and explore strategic alternatives. Additional financing is required, with no assurance it will be available on acceptable terms.
Clinical Progress: GPCR USA completed administration of its drug candidate (GPC-100) to 19 patients in Q2 2025. Results are expected to be announced in Q4 2025.
Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding the review of non-routine activities and the lack of designed controls for accounting and IT processes.
Risks: Key risks include the inability to raise capital, potential bankruptcy, uncertainty regarding the success of the GPCR USA clinical trial, and ongoing litigation (including stayed derivative lawsuits and a pending former employee breach of contract claim).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.4 million cash balance against the burn rate and the timeline for the GPCR USA clinical trial results.
- Financing Plans: Confirm if any new equity or debt financing agreements have been executed since the filing date to alleviate the going concern warning.
- Contingent Liability: Review the assumptions used to value the $5.8 million contingent consideration, specifically the probability of success for clinical milestones.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in financial reporting.
- Legal Exposure: Monitor the status of the stayed derivative lawsuits and the pending former employee litigation for potential additional costs.